tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
PremiumRatingsAnalyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
11d ago
BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab Combo
Premium
Company Announcements
BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab Combo
14d ago
BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline
Premium
Company Announcements
BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline
14d ago
AI Models Turn More Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
PremiumAI Analyst RatingsAI Models Turn More Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
17d ago
AI Models Downgrade ONC as Valuation and Weak Technicals Offset Turnaround
Premium
AI Analyst Ratings
AI Models Downgrade ONC as Valuation and Weak Technicals Offset Turnaround
19d ago
BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
Premium
The Fly
BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
24d ago
BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers
PremiumCompany AnnouncementsBeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers
1M ago
BeOne Medicines announces presentation of Phase 3 data in CLL patients
Premium
The Fly
BeOne Medicines announces presentation of Phase 3 data in CLL patients
1M ago
BeOne Medicines Advances CDK4 Cancer Drug With Completion of Key Phase 1 Trial
Premium
Company Announcements
BeOne Medicines Advances CDK4 Cancer Drug With Completion of Key Phase 1 Trial
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100